Research indicates that the disruption of signaling pathways such as Ras/Raf/MEK/ERK, p53, mammalian Target of Rapamycin (mTOR), and STAT3 in cancer may impact exosome release and subsequent proliferation. This evidence concerns the gene MAP2K7 and cancer.